Oncotarget

Vol 2, No 3

March 2011

View Archive »

Order a Reprint

About The Cover

A combination of rapamycin and metformin prevents mitotic arrest in WI-38t cells. After 24 hours, cells were microphotographed, collected and flow cytometry was performed. See Apontes et al.

Table of Contents

Commentaries

Biomarkers in NHL

Biomarkers in NHL

https://doi.org/10.18632/oncotarget.252

Sami N. Malek
102-103
PDF  |  HTML  |  Order a Reprint

Chaperones and the maturation of steroid hormone receptor complexes

Chaperones and the maturation of steroid hormone receptor complexes

https://doi.org/10.18632/oncotarget.238

Yizhi Jane Tao,  and Wenjie Zheng
104-106
PDF  |  HTML  |  Order a Reprint

Novel strategies of protecting non-cancer cells during chemotherapy: Are they ready for clinical testing?

Novel strategies of protecting non-cancer cells during chemotherapy: Are they ready for clinical testing?

https://doi.org/10.18632/oncotarget.249

Zbigniew Darzynkiewicz
107-108
PDF  |  HTML  |  Order a Reprint

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity

https://doi.org/10.18632/oncotarget.247

Linda S. Steelman, Alberto M. Martelli, Ferdinando Nicoletti,  and James A. McCubrey
109-112
PDF  |  HTML  |  Order a Reprint

Reviews

The Challenge for Gene Therapy: Innate Immune Response to Adenoviruses

The Challenge for Gene Therapy: Innate Immune Response to Adenoviruses

https://doi.org/10.18632/oncotarget.231

Bart Thaci, Ilya V. Ulasov, Derek V. Wainwright,  and Maciej S. Lesniak
113-121
Abstract  |  PDF  |  HTML  |  Order a Reprint

Recent Advances in Anti-Angiogenic Therapy of Cancer

Recent Advances in Anti-Angiogenic Therapy of Cancer

https://doi.org/10.18632/oncotarget.234

Rajeev S. Samant,  and Lalita A. Shevde
122-134
Abstract  |  PDF  |  HTML  |  Order a Reprint

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

https://doi.org/10.18632/oncotarget.240

William H. Chappell, Linda S. Steelman, Jacquelyn M. Long, Ruth C. Kempf, Stephen L. Abrams, Richard A. Franklin, Jörg Bäsecke, Franca Stivala, Marco Donia, Paolo Fagone, Graziella Malaponte, Maria C. Mazzarino, Ferdinando Nicoletti, Massimo Libra, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Giuseppe Montalto, Melchiorre Cervello, Piotr Laidler, Michele Milella, Agostino Tafuri, Antonio Bonati, Camilla Evangelisti, Lucio Cocco, Alberto M. Martelli,  and James A. McCubrey
135-164
Abstract  |  PDF  |  HTML  |  Order a Reprint

Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer

Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer

https://doi.org/10.18632/oncotarget.245

Rodrigo Dienstmann, Pablo Martinez,  and Enriqueta Felip
165-177
Abstract  |  PDF  |  HTML  |  Order a Reprint

Research Papers

IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients

IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients

https://doi.org/10.18632/oncotarget.235

Jian He, Jian Wu, Yuchen Jiao, Nina Wagner-Johnston, Richard F. Ambinder, Luis A. Diaz, Kenneth W. Kinzler, Bert Vogelstein,  and Nickolas Papadopoulos
178-185
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Inhibition of SREBP1 sensitizes cells to death ligands

Inhibition of SREBP1 sensitizes cells to death ligands

https://doi.org/10.18632/oncotarget.239

Yanina Eberhard, Marcela Gronda, Rose Hurren, Alessandro Datti, Neil MacLean, Troy Ketela, Jason Moffat, Jeffrey L. Wrana,  and Aaron D. Schimmer
186-196
Abstract  |  PDF  |  HTML  |  Order a Reprint

APC +/- alters colonic fibroblast proteome in FAP

APC +/- alters colonic fibroblast proteome in FAP

https://doi.org/10.18632/oncotarget.241

Bhavinkumar B. Patel, Xin-Ming Li, Maketa P. Dixon, Elena L. Blagoi, Emmanuelle Nicolas, Steven H, Seeholzer, David Cheng, Yin A He, Renata A Coudry, Sharon D. Howard, Dawn M. Riddle, Harry S. Cooper, Bruce M. Boman, Peggy Conrad, James A. Crowell, Alfonso Bellacosa, Alfred Knudson, Anthony T. Yeung,  and Levy Kopelovich
197-208
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib

https://doi.org/10.18632/oncotarget.246

Nickolay Neznanov, Andrei P. Komarov, Lubov Neznanova, Patricia Stanhope-Baker,  and Andrei V. Gudkov
209-221
Abstract  |  PDF  |  HTML  |  Order a Reprint

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture

https://doi.org/10.18632/oncotarget.248

Pasha Apontes, Olga V. Leontieva, Zoya N. Demidenko, Fengzhi Li,  and Mikhail V. Blagosklonny
222-233
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Research Perspectives

The RP-Mdm2-p53 Pathway and Tumorigenesis

The RP-Mdm2-p53 Pathway and Tumorigenesis

https://doi.org/10.18632/oncotarget.228

Paula L. Miliani de Marval,  and Yanping Zhang
234-238
Abstract  |  PDF  |  HTML  |  Order a Reprint

Mcl-1 Ubiquitination and Destruction

Mcl-1 Ubiquitination and Destruction

https://doi.org/10.18632/oncotarget.242

Hiroyuki Inuzuka, Hidefumi Fukushima, Shavali Shaik, Pengda Liu, Alan W. Lau,  and Wenyi Wei
239-244
Abstract  |  PDF  |  HTML  |  Order a Reprint

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders

https://doi.org/10.18632/oncotarget.233

Mayumi Naramura, Scott Nadeau, Bhopal Mohapatra, Gulzar Ahmad, Chandrani Mukhopadhay, Martin Sattler, Srikumar M. Raja, Amarnath Natarajan, Vimla Band,  and Hamid Band
245-250
Abstract  |  PDF  |  HTML  |  Order a Reprint

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

https://doi.org/10.18632/oncotarget.243

Stian Knappskog,  and Per E. Lønning
251-258
Abstract  |  PDF  |  HTML  |  Order a Reprint

A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity

A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity

https://doi.org/10.18632/oncotarget.244

Benjamin Ory,  and Leif W. Ellisen
259-264
Abstract  |  PDF  |  HTML  |  Order a Reprint

miRNA signature of schwannomas: Possible role(s) of “tumor suppressor” miRNAs in benign tumors

miRNA signature of schwannomas: Possible role(s) of “tumor suppressor” miRNAs in benign tumors

https://doi.org/10.18632/oncotarget.251

Erdogan Pekcan Erkan, Xandra O. Breakefield,  and Okay Saydam
265-270
Abstract  |  PDF  |  HTML  |  Order a Reprint


Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC